Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,764.23
(
0.35%
)
News Focus
News Focus
Post# of 257266
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: oc631 post# 163846

Thursday, 07/11/2013 4:42:01 PM

Thursday, July 11, 2013 4:42:01 PM

Post# of 257266

GILD didn't use an active comparator in any of their late-stage studies.



What do you mean? This study is Sofosbuvir plus Ribavirin. Their current NDA for treatment naive GT2/3 came from pivotal study FISSION Sofosbuvir plus Ribavirin for 12 weeks vs Pegylated interferon and ribavirin.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today